Replimune Group, Inc. (REPL) stock
REPLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
Financials through Q2 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q/A on Nov 6, 2026Score 1/30
$19.69−1.72 (-8.03%)
Close on Nov 17, 2026Market cap $1.87BP/E –Yield –
Replimune gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
No gross profit figures for Replimune
Replimune has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?